Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 264
Selected: 0
NCT IDTitle
NCT02363751Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)
NCT05041842Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
NCT00861094Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
NCT03726775Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
NCT07241273SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer
NCT06904170Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
NCT04074096Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
NCT07193394Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
NCT05440396Identifying Local Signs at the Catheter Insertion Site With Artificial Intelligence
NCT00227708Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT05639413A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NCT03169075QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program
NCT00667069Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
NCT00055731Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
NCT00002883Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
NCT01313377Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
NCT00047112Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
NCT03722680Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.
NCT01564056Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
NCT00217607Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery
NCT00006119Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
NCT02959879Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma
NCT02822482Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
NCT07259226Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
NCT00470223Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
NCT03870919Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
NCT05800275Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
NCT05973864Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT03013335Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
NCT03012581Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
NCT03006432PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA
NCT00411138Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer
NCT04357873Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
NCT03809455Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
NCT03226756Nivolumab in Recurrent and/or Metastatic SCCHN
NCT00006050Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
NCT03838263Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
NCT07360743Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
NCT04450836Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
NCT02324088Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
NCT01717924Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma
NCT01842321Abiraterone Acetate in Molecular Apocrine Breast Cancer
NCT06450314Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
NCT00003650Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
NCT03012620Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
NCT05947903Validation of the European Oncology Quality of Life Toolkit
NCT00967863Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
NCT01357486Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
NCT06446882Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
NCT01442246Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.